Pfizer Expands Voluntary Nationwide Recall to include All Lots of

CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline

Content

Media Contact: Eamonn Nolan

212-733-4626 Eamonn.Nolan@pfizer.com

FOR IMMEDIATE RELEASE - NEW YORK, NY., September 16, 2021 - Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg Tablets to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure.

Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication. The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.i

Chantix is a treatment to help patients quit smoking and is intended for short term use. People who smoke cigarettes are 15 to 30 times more likely to get lung cancer than people who do not smoke. ii

Smoking is also associated with many other cancers, as well as with cardiovascular disease and lung disease.iii CHANTIX has a safety profile that has been established over 15 years of marketing authorization and through a robust clinical program. Pfizer believes the benefit/risk profile of CHANTIX remains positive. Patients currently taking Chantix should consult with their healthcare provider about alternative treatment options. To date, Pfizer has not received reports of adverse events assessed to be related to this recall.

The NDC, Lot Number, Expiration Date, and Configuration details for Chantix Tablets are indicated in Appendix A. Photos of the products can be found in Appendix B. The products were distributed nationwide to Wholesalers and Distributors in the United States, US Virgin Islands and Puerto Rico from May 2019 to September 2021.

Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified their direct consignees by letter to arrange for return of any recalled product.

Wholesalers and Distributors with an existing inventory of Chantix tablets, should stop use and distribution and quarantine the product immediately.

If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution of the product and promptly contact Stericycle at 888-276-6166(Mon.-Fri. 8:00 am

  • 5:00 pm ET) to obtain a Business Reply Form (BRF) to initiate the return process.

If you received free product through the Pfizer Patient Assistance Program (PAP) or the Pfizer Institutional Patient Assistance

Program (IPAP), please check your stock immediately. If you have any of the product in inventory, please follow the instructions above for returning the product to Stericycle Inc. Additionally, if you are aware of any patients to whom you dispensed the products and who still may have the product in their possession, please ask them to return the product to you and then follow the instructions above for returning the product to Stericycle Inc. For any questions related to Pfizer PAP or Pfizer IPAP product, please contact 833-203-2776(Mon.-Fri. 8:00 am - 6:00 pm ET).

As communicated by FDA, there is no immediate risk to patients taking Chantix. iv Patients who are taking this product should consult with their health care provider to determine if alternate treatments are available. Patients with Chantix Tablets should contact Stericycle Inc. at 888-276-6166(Mon.-Fri. 8:00 am - 5:00 pm ET) for instructions on how to return their product and obtain reimbursement for their cost.

Healthcare Professionals with questions regarding this recall can contact Pfizer using the below information.

Contact Center

Contact Information

Area of Support

Pfizer Medical

800-438-1985, option

3

For medical

Information

(Mon.-Fri. 9 am-5 pm

ET)

questions regarding

www.pfizermedinfo.com

the product

Pfizer Drug

800-438-1985, option

1

To report adverse

Safety

(24 hours a day; 7 days

events and product

a week)

complaints

Adverse events or product complaints experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online:
  • www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download formwww.fda.gov/MedWatch/getforms.htmor call 1-800-332-1088to request a reporting form, then complete and return to the address on the pre-addressedform, or submit by fax
    to 1-800-FDA-0178.

This recall is being executed with the knowledge of the U.S. Food and Drug Administration.

# # # # #

Appendix A: Recalled Product Details

PRODUCT: Chantix Tablets, 0.5 mg

NDC: 0069-0468-56

SIZE: Bottle of 56 Tablets

EXPIRATION DATE: January 2022 - May 2023

LOT NUMERS:

00019213

DM9007

EC6994

EN8362

CY6861

DM9008

EN5725

EN8467

PRODUCT: Chantix Tablets, 1 mg

NDC: 0069-0469-56

SIZE: Bottle of 56 Tablets

EXPIRATION DATE: September 2021 - December 2023

LOT NUMBERS:

00018777

00021024

CW1572

DF5280

DY7987

EN5694

00019289

00021073

CW1573

DF5281

EA6080

EN5695

00019593

00021074

CW1574

DF5282

EC9841

EP1717

00019682

CW1565

CW1575

DR5086

EC9842

EP1718

00019846

CW1566

CW1578

DR5092

EC9843

EP1719

00019977

CW1567

CW1579

DR5093

EC9847

EW2012

00020295

CW1568

CW1581

DR5094

EC9848

EW3854

00020448

CW1569

DF5277

DT3885

EE1011

EW3865

00020458

CW1570

DF5278

DW4148

EM1069

EX2102

00020480

CW1571

DF5279

DW4152

EM1070

EX2103

PRODUCT: Chantix Tablets, 1 mg

NDC: 0069-0469-03

SIZE: Carton containing 4 blister packs of 14 tablets each

EXPIRATION DATE: September 2021 - June 2023

LOT NUMBERS:

00019431

00021421

00022765

DR2614

DY7060

EE9391

00019542

00021422

00022766

DX4576

DY9367

EF2346

00019543

00021423

00023134

DX5870

DY9473

EM4805

00019544

00022136

00023135

DX5871

DY9475

EM4807

00020814

00022174

00023747

DX5872

DY9476

EN2005

00020815

00022175

00023748

DX5873

DY9505

ET1601

00020907

00022176

DL3896

DX7805

EC5910

ET1605

00020965

00022177

DL7779

DY6078

EC5913

ET1606

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Pfizer Inc. published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 14:21:09 UTC.